National Institutes of Health Stroke Scale
Author:
Chalos Vicky123, van der Ende Nadinda A.M.13, Lingsma Hester F.2, Mulder Maxim J.H.L.1, Venema Esmee12, Dijkland Simone A.2, Berkhemer Olvert A.1345, Yoo Albert J.6, Broderick Joseph P.7, Palesch Yuko Y.8, Yeatts Sharon D.8, Roos Yvo B.W.E.M.9, van Oostenbrugge Robert J.10, van Zwam Wim H.5, Majoie Charles B.L.M.4, van der Lugt Aad3, Roozenbeek Bob13, Dippel Diederik W.J.1, Berkhemer Olvert A., Fransen Puck S.S., Beumer Debbie, van den Berg Lucie A., Lingsma Hester F., Yoo Albert J., Schonewille Wouter J., Albert Vos Jan, Nederkoorn Paul J., Wermer Marieke J.H., van Walderveen Marianne A.A., Staals Julie, Hofmeijer Jeannette, van Oostayen Jacques A., Lycklama a Nijeholt Geert J., Boiten Jelis, Brouwer Patrick A., Emmer Bart J., de Bruijn Sebastiaan F., van Dijk Lukas C., Kappelle L. Jaap, Lo Rob H., van Dijk Ewoud J., de Vries Joost, de Kort Paul L.M., van Rooij Willem Jan J., van den Berg Jan S.P., van Hasselt Boudewijn A.A.M., Aerden Leo A.M., Dallinga Rene J., Visser Marieke C., Bot Joseph C.J., Vroomen Patrick C., Eshghi Omid, Schreuder Tobien H.C.M.L., Heijboer Roel J.J., Keizer Koos, Tielbeek Alexander V., den Hertog Heleen M., Gerrits Dick G., van den Berg-Vos Renske M., Karas Giorgos B., Steyerberg Ewout W., Flach H. Zwenneke, Marquering Henk A., Sprengers Marieke E.S., Jenniskens Sjoerd F.M., Beenen Ludo F.M., van den Berg Rene, Koudstaal Peter J., van Zwam Wim H., Roos Yvo B.W.E.M., van der Lugt Aad, van Oostenbrugge Robert J., Majoie Charles B.L.M., Dippel Diederik W.J.,
Affiliation:
1. From the Departments of Neurology (V.C., N.A.M.v.d.E., M.J.H.L.M., E.V., O.A.B., B.R., D.W.J.D.), Erasmus MC University Medical Center, Rotterdam, the Netherlands 2. Public Health (V.C., H.F.L., E.V., S.A.D.), Erasmus MC University Medical Center, Rotterdam, the Netherlands 3. Radiology and Nuclear Medicine (V.C., N.A.M.v.d.E., O.A.B., A.v.d.L., B.R.), Erasmus MC University Medical Center, Rotterdam, the Netherlands 4. Departments of Radiology and Nuclear Medicine (O.A.B., C.B.L.M.M.), Amsterdam UMC, Location AMC, University of Amsterdam, the Netherlands 5. Radiology (O.A.B., W.H.v.Z.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands. 6. Department of Interventional Neuroradiology, Texas Stroke Institute, Dallas-Fort Worth (A.J.Y.) 7. Department of Neurology and Rehabilitation Medicine, University of Cincinnati Gardner Neuroscience Institute, OH (J.P.B.) 8. Department of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., S.D.Y.) 9. Neurology (Y.B.W.E.M.R.), Amsterdam UMC, Location AMC, University of Amsterdam, the Netherlands 10. Departments of Neurology (R.J.v.O.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands.
Abstract
Background and Purpose—
The modified Rankin Scale (mRS) at 3 months is the most commonly used primary outcome measure in stroke treatment trials, but it lacks specificity and requires long-term follow-up interviews, which consume time and resources. An alternative may be the National Institutes of Health Stroke Scale (NIHSS), early after stroke. Our aim was to evaluate whether the NIHSS assessed within 1 week after treatment could serve as a primary outcome measure for trials of acute treatment for ischemic stroke.
Methods—
We used data from 2 randomized controlled trials of endovascular treatment for ischemic stroke: the positive MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; N=500) and the neutral IMS (Interventional Management of Stroke) III trial (N=656). We used a causal mediation model, with linear and ordinal logistic regression adjusted for confounders, to evaluate the NIHSS 24 hours and 5 to 7 days after endovascular treatment as primary outcome measures (instead of the mRS at 3 months) in both trials. Patients who had died before the NIHSS was assessed received the maximum score of 42. NIHSS+1 was then log10-transformed.
Results—
In both trials, there was a significant correlation between the NIHSS at 24 hours and 5 to 7 days and the mRS. In MR CLEAN, we found a significant effect of endovascular treatment on the mRS and on the NIHSS at 24 hours and 5 to 7 days. After adjustment for NIHSS at 24 hours and 5 to 7 days, the effect of endovascular treatment on the mRS decreased from common odds ratio 1.68 (95% CI, 1.22–2.32) to respectively 1.36 (95% CI, 0.97–1.91) and 1.24 (95% CI, 0.87–1.79), indicating that treatment effect on the mRS is in large part mediated by the NIHSS. In the IMS III trial there was no treatment effect on the NIHSS at 24 hours and 5 to 7 days, corresponding with the absence of a treatment effect on the mRS.
Conclusions—
The NIHSS within 1 week satisfies the requirements for a surrogate end point and may be used as a primary outcome measure in trials of acute treatment for ischemic stroke, particularly in phase II(b) trials. This could reduce stroke-outcome assessment to its essentials (ie, neurological deficit), and reduce trial duration and costs. Whether and under which conditions it could be used in phase III trials requires a debate in the field with all parties.
Clinical Trial Registration—
URL:
http://www.isrctn.com
. Unique identifier: ISRCTN10888758;
https://www.clinicaltrials.gov
. Unique identifier: NCT00359424.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)
Cited by
116 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|